Evenity (Romosozumab) Re-Titration After Stopping: What Women Need to Know

What Is Romosozumab and Why Does Titration Work Differently

Romosozumab is not a traditional osteoporosis drug where dose can be adjusted up or down. The FDA-approved dose is fixed at 210 mg subcutaneously once monthly, delivered as two separate 105 mg injections administered one after the other at the same clinic or home visit. Every patient gets the same amount. There is no lower starting dose, no gradual uptitration, and no approved maintenance dose beyond 12 months.

This matters because women searching for "how to titrate Evenity" are often asking one of two very different questions: either how to start a first course correctly, or whether they can restart the drug after an interruption or after completing the original 12 doses. The answers differ, and conflating them leads to real clinical mistakes.

How the 12-Month Course Works

The mechanism drives the schedule. Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that normally suppresses bone formation. By blocking sclerostin, the drug simultaneously increases bone formation and decreases bone resorption, a dual effect no other approved osteoporosis agent replicates. This dual anabolic-antiresorptive window is time-limited. Research from the FRAME trial showed spine BMD increased by 13.3% at 12 months compared with placebo in postmenopausal women, but the bone-formation effect begins to wane before the 12-month mark even while injections continue.

Once you complete the 12th injection, bone formation markers drop back toward baseline within weeks. That is why every guideline specifying romosozumab use, including the 2022 American College of Rheumatology guidelines and The Menopause Society's 2023 position statement, recommends an immediate transition to an antiresorptive agent, typically a bisphosphonate or denosumab. Stopping without a follow-on agent causes rapid bone loss and may eliminate the fracture-risk reduction you worked 12 months to achieve.

The Two-Injection Technique

Each monthly visit involves two injections, one in the abdomen, thigh, or upper arm, and the second in a different site or at least 1 inch away from the first. The FDA label specifies that both injections should be given consecutively to ensure the full 210 mg dose is received in a single session. Neither injection can be substituted by oral medication or split across different days.

Re-Titration After Stopping: What the Evidence Actually Shows

This is where most online content fails women. The question of restarting romosozumab after stopping is clinically relevant, but the evidence base is thin. There is no completed phase 3 RCT that enrolled postmenopausal women specifically to receive a second sequential 12-month course of romosozumab after a gap.

What Happened in the ARCH Trial

The ARCH trial (alendronate-controlled, published in NEJM 2017) compared 12 months of romosozumab 210 mg monthly followed by alendronate, versus alendronate alone in postmenopausal women with a prior vertebral fracture. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fracture risk by 48% and clinical fracture risk by 27% compared with alendronate alone. What ARCH did not include was a re-treatment arm where women who completed one course of romosozumab stopped, had a gap, and then received a second course.

The ARCH data do confirm one thing clearly: the gains made during 12 months of romosozumab are substantially preserved when an antiresorptive follows immediately. Women in the active arm who transitioned to alendronate maintained most of their BMD gains through 24 months. Women who received no follow-on therapy after anabolic agents in parallel teriparatide studies lost gains rapidly, and there is reason to believe the same applies to romosozumab.

Why Re-Treatment Data Is So Sparse

The practical framework for thinking about romosozumab re-treatment comes from the biology of sclerostin inhibition. After 12 months of therapy, sclerostin levels rebound and bone formation markers return toward pretreatment values. A theoretical rationale exists for a second course: if a woman's fracture risk remains very high after completing a course and transitioning to an antiresorptive, a second cycle of romosozumab might generate additional anabolic benefit. This logic mirrors what has been observed with teriparatide re-treatment data in small studies. But it remains theoretical for romosozumab. No phase 3 trial has confirmed fracture risk reduction with a repeat course, and no regulatory authority has approved it. Any clinician offering a second course is acting outside the label, which must be disclosed to you as the patient.

The American Society for Bone and Mineral Research (ASBMR) task force on sequential therapy has noted the absence of re-treatment trial data as a specific gap, and the Endocrine Society's 2020 clinical practice guideline on osteoporosis in postmenopausal women does not include romosozumab re-treatment as a recommended option.

What Clinicians Are Doing in Practice

In the absence of RCT data, some bone specialists are offering a second course to women with very high fracture risk, persistently low T-scores despite prior therapy, or documented intolerance to antiresorptive agents. This practice is not supported by outcomes data and carries the same cardiovascular risk profile as the original course. If your specialist proposes a second cycle, you are entitled to ask: what evidence supports this for fracture reduction specifically, and has my cardiovascular risk been formally re-evaluated?

Cardiovascular Risk: The Black Box Warning Every Woman Must Understand

Romosozumab carries a Black Box Warning for serious cardiovascular events, specifically myocardial infarction and stroke. In the ARCH trial, serious cardiovascular events occurred in 2.5% of women in the romosozumab group versus 1.9% in the alendronate group during the first 12 months. That 0.6 percentage point difference was small in absolute terms but statistically significant and led to the boxed warning.

The FDA label states that romosozumab should not be started in women who have had a myocardial infarction or stroke within the preceding year. For women considering a second course, cardiovascular risk must be formally re-evaluated, not assumed to be the same as at the first course start. Postmenopausal women accumulate cardiovascular risk with age. A woman who had no major CV events at age 62 during her first course may have developed new risk factors, new atherosclerotic burden, or new co-morbidities by age 64 or 65 when a second course is being considered.

Your prescribing clinician should review a current lipid panel, blood pressure status, glycemic control, and any interim cardiac symptoms before a second course is initiated. This is not optional paperwork. It is the safety basis for the most important decision point in romosozumab re-treatment.

Pregnancy, Lactation, and Contraception

Romosozumab is contraindicated in pregnancy. The drug is approved only for postmenopausal women, and there are no adequate human data on use during pregnancy. Animal studies showed fetal harm at doses below the human clinical dose, including increased rates of fetal loss and skeletal abnormalities in rodent and primate models.

Who This Warning Affects in Practice

Romosozumab's approval is limited to postmenopausal women, so most prescribers will never consider it in someone with reproductive potential. But "postmenopausal" is a clinical determination that requires care. Perimenopause involves irregular cycles and intermittent ovulation. A woman who has had 10 months without a period, begins romosozumab, and then experiences a spontaneous cycle and unintended pregnancy has used a teratogenic agent in early gestation. This edge case is rare but not impossible.

Premenopausal women with osteoporosis secondary to conditions like anorexia nervosa, premature ovarian insufficiency, or glucocorticoid use should not receive romosozumab. ACOG and ASRM guidance on bone health in reproductive-age women does not include romosozumab as an option for this group.

Lactation

Transfer of romosozumab into human breast milk has not been studied. Given the molecular weight of the antibody and the potential for neonatal exposure through milk, use during breastfeeding is not recommended. This is consistent with how most therapeutic monoclonal antibodies are handled in the absence of lactation-specific pharmacokinetic data.

Contraception Requirements

Because romosozumab is not approved outside postmenopausal status, formal contraception requirements are not specified in the label the way they are for teratogenic drugs used in reproductive-age women (such as isotretinoin or thalidomide). However, any clinician prescribing romosozumab to a woman whose menopausal status is uncertain, such as someone in early postmenopause under age 52, should confirm 12 consecutive months of amenorrhea and consider FSH confirmation before initiating.

How Romosozumab Fits Across Life Stages

Postmenopausal Women (Primary Indication)

This is the only approved population. The inflection point for clinical consideration is a woman with a T-score of <-2.5 at the spine or hip, or a T-score of <-1.0 with a prior vertebral or hip fracture, or a 10-year FRAX hip fracture probability above 3% or major osteoporotic fracture probability above 20%. The Menopause Society's 2023 position on osteoporosis identifies romosozumab as a first-line anabolic option for women at very high fracture risk, specifically those with prior vertebral fracture or very low T-scores.

Age matters within this group. Women in their late 50s and early 60s typically carry lower baseline cardiovascular risk, making the Black Box Warning less restrictive for them. Women in their mid-70s and beyond may have accumulated CV risk factors that push the risk-benefit calculation toward bisphosphonates or denosumab as preferred agents.

Perimenopause

Romosozumab is not approved for perimenopausal women. Bone loss accelerates in the 2 to 3 years before and immediately after the final menstrual period, sometimes at a rate of 2 to 3% per year at the spine. But this acceleration responds to estrogen therapy, which remains the first-line agent for bone preservation in symptomatic perimenopausal women under age 60 or within 10 years of menopause. The Menopause Society supports hormone therapy as an appropriate bone-protective treatment in early postmenopause, and it is the preferable option before switching to a bone-specific agent like romosozumab.

Women With PCOS or Secondary Amenorrhea

Chronic anovulation, low estrogen exposure, and hyperprolactinemia can impair bone accrual in reproductive-age women with PCOS or functional hypothalamic amenorrhea. These women may present with low bone density at a relatively young age. Romosozumab is not an appropriate treatment here. Evidence for its use in premenopausal women with low bone density is absent, and the cardiovascular risk profile has not been studied in this population. The correct approach is restoring estrogen either through hormonal contraception or transdermal estradiol plus a progestin.

Sequential Therapy: Why What Comes After Romosozumab Matters as Much as the Drug Itself

Completing 12 months of romosozumab without a follow-on antiresorptive is a clinical mistake. The FRAME extension data showed that women who transitioned to denosumab after romosozumab continued to gain BMD for an additional 12 months, reaching a mean spine BMD increase of approximately 17% from baseline at 24 months. Women who received placebo after romosozumab lost a substantial portion of their bone density gains within 12 months.

Choosing the Right Follow-On Agent

Two main options exist after romosozumab:

Bisphosphonates (alendronate, zoledronic acid, risedronate): These are the most common transition agents. The ARCH trial used alendronate as the comparator antiresorptive, supporting the evidence base for this sequence. Alendronate 70 mg weekly orally is typical, or zoledronic acid 5 mg IV annually for women who cannot tolerate oral bisphosphonates due to GI side effects.

Denosumab (Prolia): Denosumab 60 mg subcutaneously every 6 months is an alternative for women with impaired renal function who cannot safely take bisphosphonates, or for women who prefer injectable over oral therapy. One caution: stopping denosumab without a bisphosphonate bridge causes rapid bone loss and rebound vertebral fractures. The transition from romosozumab to denosumab to discontinuation requires very careful planning.

The choice between bisphosphonate and denosumab is individualized by renal function, GI tolerance, fracture history, and patient preference. This decision should happen before romosozumab dose 12, not after the last injection.

Who This Treatment Is Right For (and Who Should Avoid It)

Women Most Likely to Benefit

Women who are most likely to experience a meaningful benefit from romosozumab share a clear profile: postmenopausal status confirmed by 12 months of amenorrhea, a prior vertebral or hip fracture, or a T-score at or below <-2.5, no history of MI or stroke in the past 12 months, and either prior bisphosphonate therapy with inadequate response or a baseline fracture risk high enough to warrant the faster BMD gains that an anabolic agent provides. The ARCH trial enrolled women with a mean age of 74 and a prior vertebral fracture, and this remains the population with the strongest supporting evidence.

Women Who Should Avoid It

Absolute contraindications or strong cautions include: pregnancy or uncertain menopausal status, MI or stroke within the past year, known hypocalcemia (must be corrected before starting), hypersensitivity to romosozumab or any ingredient in the formulation, and women who are unwilling or unable to commit to follow-on antiresorptive therapy after the 12-month course.

Women with severe renal impairment (GFR <30 mL/min) can technically receive romosozumab because it is not renally cleared, but they carry higher baseline cardiovascular risk, which requires more careful case-by-case assessment.

Monitoring During and After a Course

Monitoring during a 12-month course involves:

• Serum calcium before each injection if hypocalcemia is a concern
• Dental evaluation before starting (jaw osteonecrosis risk, though lower with romosozumab than with antiresorptives, is not zero)
• Blood pressure and cardiovascular symptoms review at each visit
• DXA scan at 12 months to document response before transitioning therapy
• Bone turnover markers (P1NP for formation, CTX for resorption) at months 1 to 3 to confirm pharmacologic response

After completing the course and transitioning to an antiresorptive, DXA monitoring follows the standard interval of every 1 to 2 years depending on baseline risk and clinical stability.

Evidence Gaps Specific to Women

Women have been the majority of participants in romosozumab trials because osteoporosis disproportionately affects women, so the sex-specific evidence base is stronger here than in many other drug classes. Both FRAME (postmenopausal women vs. Placebo) and ARCH (postmenopausal women vs. Alendronate) enrolled exclusively or near-exclusively female populations. Several gaps remain.

Black and Hispanic women were under-represented in both trials. The FRAME trial enrolled women from 47 countries, but the proportion of non-White participants in the US sub-cohort was not reflective of US demographic diversity. Given that fracture risk assessment tools like FRAX may underestimate risk in some racial groups, and that bone geometry differs by ethnicity, applying the FRAME and ARCH results uniformly across all postmenopausal women requires caution.

Data on romosozumab in women with PCOS, premature ovarian insufficiency, or glucocorticoid-induced osteoporosis in premenopausal women is absent. These women need dedicated study.

"Romosozumab represents the clearest example we have of a drug where the follow-on therapy is as important as the drug itself," says Rachel Goldberg, MD, WomanRx editorial board member and board-certified obstetrician-gynecologist. "When women ask me about restarting Evenity after stopping, my first question is always: did you complete a full 12-month course, and what antiresorptive came next? The answers tell me almost everything about what the bone density situation looks like now."